Nephrotic Syndrome| A Pipeline Analysis Report 2018| Technavio

Technavio has announced their latest pipeline analysis report on the nephrotic
syndrome market. The report includes a detailed analysis of the
pipeline molecules under investigation within the defined data
collection period to treat nephrotic syndrome.

This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20180710005824/en/

Technavio has published a new report on the drug development pipeline for nephrotic syndrome, including a detailed study of the pipeline molecules. (Photo: Business Wire)

This report by Technavio
presents a detailed analysis of the market, including regulatory
framework, drug development strategies, recruitment strategies, and key
companies that are expected to play an essential role in the growth of
the market in the future.

THIS REPORT IS AVAILABLE AT A USD 1,000 DISCOUNT FOR A LIMITED TIME
ONLY: VIEW
MARKET SNAPSHOT BEFORE PURCHASING

Nephrotic syndrome: Market overview

The nephrotic syndrome occurs when the cluster of blood vessels in the
kidney, which helps in the filtration of waste and excess water, gets
damaged. This causes excessive excretion of protein through the urine
and loss of fluid from the body that may lead to high blood cholesterol
levels and high blood pressure. The symptoms of nephrotic syndrome
include severe swelling in the eyes, feet, and ankles, foamy urine due
to excess loss of protein in urine, weight gain, fatigue, and loss of
appetite.

According to a senior market research analyst at Technavio, “Nephrotic
syndrome is one of the most prominent kidney diseases. According to a
research in 2016, 4.9 million adults in the US were diagnosed with
kidney disorders, which accounts for 2% of the total.”

Nephrotic syndrome: Segmentation analysis

This pipeline analysis report segments the nephrotic syndrome market
based on therapies employed (monotherapy), RoA
(intravenous/subcutaneous, oral, and intravenous), therapeutic
modalities (biological, small molecule, peptide, and fusion protein),
drugs under development (CCR2 receptor, glucocorticoid receptor, inosine
morphosphate dehydrogenase, melanocortin-2 receptor, renin, CD 80 and CD
86, endothelin-A receptor), MoA (CCR2 receptor antagonist,
glucocorticoid receptor agonist, inosine morphosphate dehydrogenase
inhibitor, melanocortin-2 receptor agonist, renin inhibitor, CD 80 and
CD 86 inhibitors, endothelin-A receptor antagonist), geographical
segmentation (US, China, and Belgium) and recruitment status (active,
not recruiting, completed, recruiting). It provides an in-depth analysis
of the prominent factors influencing the market, including drivers,
opportunities, trends, and industry-specific challenges.

LOOKING FOR MORE INFORMATION ON THIS MARKET? REQUEST
A FREE SAMPLE REPORT

Technavio’s sample reports are free of charge and contain multiple
sections of the report such as the market size and forecast, drivers,
challenges, trends, and more.

Some of the key topics covered in the report include:

Scope of the Report

Regulatory Framework

Drug Development Landscape

Drug Development Strategies

Recruitment Strategies

Key Companies

Discontinued or Dormant Molecules

About Technavio

Technavio
is a leading global technology research and advisory company. Their
research and analysis focuses on emerging market trends and provides
actionable insights to help businesses identify market opportunities and
develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists
of more than 10,000 reports and counting, covering 800 technologies,
spanning across 50 countries. Their client base consists of enterprises
of all sizes, including more than 100 Fortune 500 companies. This
growing client base relies on Technavio’s comprehensive coverage,
extensive research, and actionable market insights to identify
opportunities in existing and potential markets and assess their
competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team
at media@technavio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180710005824/en/

Leave a Comment